Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

52.50 -0.14 (-0.27%)
Official Closing Price Updated: 7:00 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
64 65 Next >
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb
Via Benzinga
Is Exelixis Stock a Buy Now?
Don't be too quick to dismiss this company as a one-trick pony. 
Via The Motley Fool
This House of Representative Just Sold Up To $250K In Bristol-Myers Squibb Stock
Via Benzinga
Investors Should Consider This Warren Buffett Advice in 2023
If investors wait too long to buy stocks, they're in danger of missing out on the inevitable rally. 
Via The Motley Fool
20 Recession-Proof Stocks to Buy Now for 2023
These recession-proof stocks typically hold up better in a recession and add diversity to your portfolio. 
Via The Motley Fool
Congressman Sells Stocks At End Of 2022 And Retires From Office: Taking Profits Or Warning Sign?
A member of Congress sold out of his positions in several stocks at the end of 2022. The move came as he finished his term serving the state of Texas and announced his retirement. 
Via Benzinga
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
From Bristol Myers Squibb
Via Business Wire
23 Top Dividend Stocks to Buy and Hold in 2023
These dividend stocks could reward investors in the new year and beyond. 
Via The Motley Fool
See a Recession in 2023? Stock Up on These 3 Ultra-Safe Dividend Stocks.
These dividend stocks should easily withstand a recession. 
Via The Motley Fool
You Can Boost Your Passive Income With These 3 Dividend Raises
A trio of top companies in the agricultural machinery, waste removal, and pharmaceutical industries recently enhanced their shareholder payouts. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
Healthcare is a sector that has proven to be reliable in recessions. 
Via The Motley Fool
10 Top Dividend Stocks To Buy For 2023
These high-quality dividend stocks could outperform the market in 2023 
Via The Motley Fool
My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023
The momentum for these high-flying stocks should continue in the new year. 
Via The Motley Fool
6 Stocks Warren Buffett Completely Exited in 2022
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Dividend Stocks to Buy and Hold Through 2023 and Beyond
These pharma giants are crushing the broader market this year. 
Via The Motley Fool
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
From Bristol Myers Squibb
Via Business Wire
TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study
Via Benzinga
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. 
Via Investor's Business Daily
Bristol-Myers Squibb's Debt Overview
Shares of Bristol-Myers Squibb Inc. (NYSE:BMY) moved higher by 10.05% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look... 
Via Benzinga
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
FDA action on its KRAS-blocking drug could help recently downtrodden Mirati. 
Via Investor's Business Daily
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.